Compare Natera Inc. Common Stock (NTRA) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Zillow Group Inc Class A — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Zillow Group Inc Class A trades at $29.53 (market cap $6.33B). The key difference: Natera Inc. Common Stock is far larger — about 9× Zillow Group Inc Class A's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Zillow Group Inc Class A for 86 Days on average.
| NTRA | ZG | |
|---|---|---|
Market Cap | $57.03B | $6.33B |
Volume | 1,131,157 | 1,202,678 |
Sector | Health | Media |
52-Week High | $425.64 | $74.58 |
52-Week Low | $179.42 | $27.70 |
Typical Hold Time | 0 Days | 86 Days |
Enterprise Value | $56.18B | $6.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Zillow Group (ZG) trades at $29.27, up 2.02% today, amid a challenging housing market. The stock is technically bearish, trading near its pivot point of $29, with key resistance at $30 and support at $28. Fundamentally, the company has returned to profitability in 2025 with a net income of $23 million, a significant improvement from prior years' losses, though its P/E ratio of 125.43 remains high. Recent news highlights competitive pressures and interest rate sensitivity.
The outlook is mixed. Analyst consensus is a 'Hold' with a $48.60 price target, implying substantial upside, but execution on its integrated transaction platform and navigating housing affordability headwinds are key. Risks include market volatility and a high valuation. The path to sustained profitability will be the primary driver for the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
